BRPI0918838A2 - processos para preparação de composições de polipeptídeos purificados - Google Patents

processos para preparação de composições de polipeptídeos purificados

Info

Publication number: BRPI0918838A2
Authority: BR; Brazil
Prior art keywords: processes; purified polypeptide; polypeptide compositions; preparing purified; preparing
Prior art date: 2008-09-22

Application number

BRPI0918838A

Other languages

English (en)

Inventor

Christopher Leitheiser

Huw M Nash

Matthew Iadanza

Noriyuki Kawahata

Original Assignee

Aileron Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-22

Filing date

2009-09-22

Publication date

2015-12-08

2009-09-22 Application filed by Aileron Therapeutics Inc filed Critical Aileron Therapeutics Inc

2015-12-08 Publication of BRPI0918838A2 publication Critical patent/BRPI0918838A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Analytical Chemistry (AREA)
Obesity (AREA)
Pulmonology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Endocrinology (AREA)

BRPI0918838A 2008-09-22 2009-09-22 processos para preparação de composições de polipeptídeos purificados BRPI0918838A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9909908P	2008-09-22	2008-09-22
PCT/US2009/057931 WO2010034032A2 (en)	2008-09-22	2009-09-22	Methods for preparing purified polypeptide compositions

Publications (1)

Publication Number	Publication Date
BRPI0918838A2 true BRPI0918838A2 (pt)	2015-12-08

Family

ID=41693036

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918838A BRPI0918838A2 (pt)	2008-09-22	2009-09-22	processos para preparação de composições de polipeptídeos purificados

Country Status (9)

Country	Link
US (5)	US9206223B2 (pt)
EP (2)	EP2342221B1 (pt)
JP (5)	JP2012503025A (pt)
CN (2)	CN102203126A (pt)
AU (1)	AU2009294875C1 (pt)
BR (1)	BRPI0918838A2 (pt)
CA (1)	CA2737921C (pt)
IL (2)	IL211837A (pt)
WO (1)	WO2010034032A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7981998B2 (en) *	2006-12-14	2011-07-19	Aileron Therapeutics, Inc.	Bis-sulfhydryl macrocyclization systems
WO2008076904A1 (en)	2006-12-14	2008-06-26	Aileron Therapeutics, Inc.	Bis-sulfhydryl macrocyclization systems
TWI433674B (zh)	2006-12-28	2014-04-11	Infinity Discovery Inc	環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2952522B1 (en)	2007-01-31	2019-10-30	Dana-Farber Cancer Institute, Inc.	Stabilized p53 peptides and uses thereof
CA2678941C (en)	2007-02-23	2018-11-27	Aileron Therapeutics, Inc.	Triazole macrocycle systems
ES2610531T3 (es)	2007-03-28	2017-04-28	President And Fellows Of Harvard College	Polipéptidos cosidos
CN101917853B (zh)	2007-12-27	2014-03-19	无限药品股份有限公司	立体选择性还原的方法
CA2737921C (en)	2008-09-22	2019-01-15	Aileron Therapeutics, Inc.	Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
AU2009294877C1 (en)	2008-09-22	2015-05-07	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
BRPI0920899A2 (pt)	2008-11-24	2016-04-26	Aileron Therapeutics Inc	macrociclos peptidomiméticos com propriedades melhoradas
AU2010204648B2 (en)	2009-01-14	2016-09-01	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
CA2769795C (en)	2009-08-05	2020-01-07	Infinity Pharmaceuticals, Inc.	Enzymatic transamination of cyclopamine analogs
AU2010298338A1 (en)	2009-09-22	2012-04-12	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
RU2582678C2 (ru)	2010-08-13	2016-04-27	Эйлерон Терапьютикс, Инк.	Пептидомиметические макроциклы
WO2012037217A1 (en) *	2010-09-14	2012-03-22	Infinity Pharmaceuticals, Inc.	Transfer hydrogenation of cyclopamine analogs
EP2651964B1 (en)	2010-12-15	2018-02-28	The Research Foundation of State University of New York	Cross-linked peptides and proteins, methods of making same, and uses thereof
ES2594828T3 (es) *	2011-06-03	2016-12-22	Hetero Research Foundation	Procedimiento para fosaprepitant
AR088392A1 (es)	2011-10-18	2014-05-28	Aileron Therapeutics Inc	Macrociclos peptidomimeticos
MX362492B (es) *	2012-02-15	2019-01-21	Aileron Therapeutics Inc	Macrociclos peptidomiméticos.
US8987414B2 (en)	2012-02-15	2015-03-24	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013337388B2 (en)	2012-11-01	2018-08-02	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en)	2013-03-06	2014-09-12	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and use thereof in regulating hif1alpha
MX363522B (es)	2013-03-21	2019-03-26	Sanofi Aventis Deutschland	Síntesis de productos peptídicos que contienen hidantoína.
ES2624961T3 (es)	2013-03-21	2017-07-18	Sanofi-Aventis Deutschland Gmbh	Síntesis de productos de péptido que contienen imida cíclica
WO2015035097A1 (en)	2013-09-04	2015-03-12	California Institute Of Technology	Functionalized linear and cyclic polyolefins
WO2015038938A1 (en)	2013-09-13	2015-03-19	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
EP3564256A1 (en) *	2013-10-28	2019-11-06	Naurex Inc.	Nmda receptor modulators
KR102455171B1 (ko)	2013-12-18	2022-10-14	더 스크립스 리서치 인스티튜트	변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
JP6642887B2 (ja) *	2014-04-02	2020-02-12	ユニバーシティーオブロチェスター	アルファヘリックスを模倣した大環状ペプチドミメティック
BR112017005598A2 (pt) *	2014-09-24	2017-12-12	Aileron Therapeutics Inc	macrociclos peptidomiméticos e usos dos mesmos
AU2015320545C1 (en)	2014-09-24	2020-05-14	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko)	2015-03-20	2017-11-27	에일러론 테라퓨틱스 인코포레이티드	펩티드모방 거대고리 및 이의 용도
CA2988289C (en)	2015-06-04	2023-12-05	PellePharm, Inc.	Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10059741B2 (en)	2015-07-01	2018-08-28	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
JP2018528217A (ja)	2015-09-10	2018-09-27	エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
KR20180128022A (ko) *	2016-03-21	2018-11-30	에일러론 테라퓨틱스 인코포레이티드	펩티드 모방 거대고리에 대한 동반 진단 도구
EP3706771A4 (en)	2017-11-09	2022-05-18	WNTRX Pharmaceuticals Inc.	BCL9 PEPTIDES AND VARIANTS THEREOF
US11091522B2 (en)	2018-07-23	2021-08-17	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4730006A (en)	1986-01-27	1988-03-08	Merrell Dow Pharmaceuticals Inc.	Derivatives of 2,6-diamino-3-haloheptanedioic acid
US5094951A (en) *	1988-06-21	1992-03-10	Chiron Corporation	Production of glucose oxidase in recombinant systems
US5120859A (en)	1989-09-22	1992-06-09	Genentech, Inc.	Chimeric amino acid analogues
US5712418A (en)	1989-10-23	1998-01-27	Research Corporation Technologies, Inc.	Synthesis and use of amino acid fluorides as peptide coupling reagents
DE69118826T2 (de)	1990-11-27	1996-11-14	Fuji Photo Film Co Ltd	Propenamidderivate, deren Polymere, Copolymere und deren Verwendung
US5364851A (en)	1991-06-14	1994-11-15	International Synthecon, Llc	Conformationally restricted biologically active peptides, methods for their production and uses thereof
US5312940A (en)	1992-04-03	1994-05-17	California Institute Of Technology	Ruthenium and osmium metal carbene complexes for olefin metathesis polymerization
JP3067031B2 (ja)	1992-04-03	2000-07-17	カリフォルニアインスティチュートオブテクノロジー	オレフィンメタセシス重合方法
US5411860A (en)	1992-04-07	1995-05-02	The Johns Hopkins University	Amplification of human MDM2 gene in human tumors
EP0672059A1 (en) *	1992-11-18	1995-09-20	The Du Pont Merck Pharmaceutical Company	CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
US5446128A (en)	1993-06-18	1995-08-29	The Board Of Trustees Of The University Of Illinois	Alpha-helix mimetics and methods relating thereto
US5622852A (en)	1994-10-31	1997-04-22	Washington University	Bcl-x/Bcl-2 associated cell death regulator
US5824483A (en)	1994-05-18	1998-10-20	Pence Inc.	Conformationally-restricted combinatiorial library composition and method
IL109943A (en)	1994-06-08	2006-08-01	Develogen Israel Ltd	Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en)	1994-06-08	2002-06-18	Peptor Limited	Conformationally constrained backbone cyclized peptide analogs
US5807746A (en)	1994-06-13	1998-09-15	Vanderbilt University	Method for importing biologically active molecules into cells
US7553929B2 (en)	1994-06-13	2009-06-30	Vanderbilt University	Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5770377A (en)	1994-07-20	1998-06-23	University Of Dundee	Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5672584A (en)	1995-04-25	1997-09-30	The University Of Kansas	Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US6184344B1 (en)	1995-05-04	2001-02-06	The Scripps Research Institute	Synthesis of proteins by native chemical ligation
SI0832096T1 (en)	1995-05-04	2001-12-31	Scripps Research Inst	Synthesis of proteins by native chemical ligation
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US6051554A (en)	1995-06-07	2000-04-18	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en)	1995-06-12	1998-09-22	California Institute Of Technology	Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5831108A (en)	1995-08-03	1998-11-03	California Institute Of Technology	High metathesis activity ruthenium and osmium metal carbene complexes
AU6162996A (en) *	1996-01-17	1997-08-11	California Institute Of Technology	Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
US5663316A (en)	1996-06-18	1997-09-02	Clontech Laboratories, Inc.	BBC6 gene for regulation of cell death
US7083983B2 (en)	1996-07-05	2006-08-01	Cancer Research Campaign Technology Limited	Inhibitors of the interaction between P53 and MDM2
US5955593A (en)	1996-09-09	1999-09-21	Washington University	BH3 interacting domain death agonist
US20020064546A1 (en)	1996-09-13	2002-05-30	J. Milton Harris	Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en)	1996-09-20	1999-10-12	Idun Pharmaceuticals	Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en)	1996-10-18	1999-01-05	Washington University	Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en)	1996-11-06	2001-08-07	Genentech, Inc.	Constrained helical peptides and methods of making same
WO1998022122A1 (en)	1996-11-21	1998-05-28	Promega Corporation	Alkyl peptide amides and applications
JP3930058B2 (ja)	1997-06-25	2007-06-13	チバスペシャルティケミカルズホールディングインコーポレーテッド	ルテニウム及びオスミウムカルベン触媒
CA2304124A1 (en)	1997-09-17	1999-03-25	The Walter And Eliza Hall Institute Of Medical Research	Bci-2-like protein bim and methods of use thereof
US6165732A (en)	1997-10-14	2000-12-26	Washington University	Method for identifying apoptosis modulating compounds
US6875594B2 (en)	1997-11-13	2005-04-05	The Rockefeller University	Methods of ligating expressed proteins
CA2316834C (en)	1998-01-07	2006-01-03	Shearwater Polymers, Inc.	Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6030997A (en)	1998-01-21	2000-02-29	Eilat; Eran	Acid labile prodrugs
AU767185B2 (en)	1998-03-23	2003-11-06	President And Fellows Of Harvard College	Synthesis of compounds and libraries of compounds
DE19815275B4 (de)	1998-04-06	2009-06-25	Evonik Degussa Gmbh	Alkylidenkomplexe des Rutheniums mit N-heterozyklischen Carbenliganden und deren Verwendung als hochaktive, selektive Katalysatoren für die Olefin-Metathese
UA72460C2 (en)	1998-04-15	2005-03-15	Aventic Pharmaceuticals Inc	A process for the preparation of polymer- bound cyclic peptides
US6326354B1 (en)	1998-08-19	2001-12-04	Washington University	Modulation of apoptosis with bid
US7173005B2 (en)	1998-09-02	2007-02-06	Antyra Inc.	Insulin and IGF-1 receptor agonists and antagonists
CA2368431C (en)	1999-03-29	2006-01-24	The Procter & Gamble Company	Melanocortin receptor ligands
US6713280B1 (en)	1999-04-07	2004-03-30	Thomas Jefferson University	Enhancement of peptide cellular uptake
US7192713B1 (en)	1999-05-18	2007-03-20	President And Fellows Of Harvard College	Stabilized compounds having secondary structure motifs
EP1180108B1 (en)	1999-05-24	2003-08-27	California Institute Of Technology	Imidazolidine-based metal carbene metathesis catalysts
US6348558B1 (en)	1999-12-10	2002-02-19	Shearwater Corporation	Hydrolytically degradable polymers and hydrogels made therefrom
US6495674B1 (en)	2000-02-25	2002-12-17	The Salk Institute For Biological Studies	Evectins and their use
US7049290B2 (en)	2000-07-28	2006-05-23	Universität Zürich	Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
US6921735B2 (en)	2000-08-10	2005-07-26	The Trustees Of Boston College	Recyclable metathesis catalysts
US6703382B2 (en)	2000-08-16	2004-03-09	Georgetown University Medical Center	Small molecule inhibitors targeted at Bcl-2
JP2004530422A (ja)	2000-12-19	2004-10-07	ザジョンズホプキンスユニバーシティ	急速なアポトーシスを誘導するｊｆｙ１蛋白質
AU2002364364A1 (en)	2001-12-31	2003-07-24	Dana-Farber Cancer Institute, Inc.	Method of treating apoptosis and compositions thereof
CN100419426C (zh)	2002-04-22	2008-09-17	佛罗里达州立大学	功能化纳米微粒及其使用方法
SE0201863D0 (en)	2002-06-18	2002-06-18	Cepep Ab	Cell penetrating peptides
JP2006516383A (ja)	2002-09-09	2006-07-06	デイナ−ファーバーキャンサーインスティチュート，インコーポレイテッド	Ｂｈ３ペプチドおよびその使用方法
CN101003459B (zh) *	2002-10-24	2011-08-10	陶氏环球技术有限责任公司	烯烃易位产物混合物的稳定
CN1711084B (zh)	2002-11-08	2010-04-28	霍夫曼-拉罗奇有限公司	作为ppar激动剂的取代4-烷氧基噁唑衍生物
US7166575B2 (en)	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20070032417A1 (en)	2002-12-24	2007-02-08	Walter And Eliza Hall Institute Of Medical Research	Peptides and therapeutic uses thereof
JP2007537989A (ja)	2003-10-16	2007-12-27	アプラーゲンゲゼルシャフトミットベシュレンクテルハフツング	安定化ペプチド
EP2332968B1 (en) *	2003-11-05	2016-05-04	Dana-Farber Cancer Institute, Inc.	Alpha-helical peptides suitable for activating or inhibiting cell death
GB0404731D0 (en)	2004-03-03	2004-04-07	Indp Administrative Inst Nims	Method and products for the selective degradation of proteins
EP1737884B1 (en)	2004-03-19	2016-10-19	The University Of Queensland	Alpha helical mimics, their uses and methods for their production
WO2005118620A2 (en)	2004-05-27	2005-12-15	New York University	Methods for preparing internally constraied peptides and peptidomimetics
US7501397B2 (en)	2004-06-04	2009-03-10	The Brigham And Women's Hospital, Inc.	Helical peptidomimetics with enhanced activity
WO2006103666A2 (en)	2005-03-28	2006-10-05	Yeda Research And Development Co. Ltd.	Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
CN1907992B (zh)	2005-07-04	2012-03-28	赞南科技(上海)有限公司	钌络合物配体、钌络合物、固载钌络合物催化剂及其制备方法和用途
CA2614073C (en)	2005-07-04	2016-05-03	Zheng-Yun Zhan	Ruthenium complexes comprising chelating alkylidene ligands
US7745573B2 (en)	2006-02-17	2010-06-29	Polychip Pharmaceuticals Pty Ltd.	Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7538190B2 (en)	2006-02-17	2009-05-26	Polychip Pharmaceuticals Pty Ltd	Methods for the synthesis of two or more dicarba bridges in organic compounds
GB0611405D0 (en)	2006-06-09	2006-07-19	Univ Belfast	FKBP-L: A novel inhibitor of angiogenesis
WO2008061192A2 (en)	2006-11-15	2008-05-22	Dana-Farber Cancer Institute, Inc.	Stabilized maml peptides and uses thereof
US7981998B2 (en)	2006-12-14	2011-07-19	Aileron Therapeutics, Inc.	Bis-sulfhydryl macrocyclization systems
WO2008076904A1 (en)	2006-12-14	2008-06-26	Aileron Therapeutics, Inc.	Bis-sulfhydryl macrocyclization systems
EP2952522B1 (en) *	2007-01-31	2019-10-30	Dana-Farber Cancer Institute, Inc.	Stabilized p53 peptides and uses thereof
CA2678941C (en)	2007-02-23	2018-11-27	Aileron Therapeutics, Inc.	Triazole macrocycle systems
ES2610531T3 (es)	2007-03-28	2017-04-28	President And Fellows Of Harvard College	Polipéptidos cosidos
CA2700925C (en)	2007-09-26	2016-08-23	Dana Farber Cancer Institute	Methods and compositions for modulating bcl-2 family polypeptides
WO2009126292A2 (en)	2008-04-08	2009-10-15	Aileron Therapeutics, Inc.	Biologically active peptidomimetic macrocycles
US20110144303A1 (en)	2008-04-08	2011-06-16	Aileron Therapeutics, Inc.	Biologically Active Peptidomimetic Macrocycles
CA2737921C (en)	2008-09-22	2019-01-15	Aileron Therapeutics, Inc.	Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
CA2737918A1 (en)	2008-09-22	2010-03-25	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
AU2009294877C1 (en)	2008-09-22	2015-05-07	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
BRPI0920899A2 (pt)	2008-11-24	2016-04-26	Aileron Therapeutics Inc	macrociclos peptidomiméticos com propriedades melhoradas
EP2488193A4 (en)	2009-10-14	2013-07-03	Aileron Therapeutics Inc	IMPROVED PEPTIDOMIMETIC MACROCYCLES

2009
- 2009-09-22 CA CA2737921A patent/CA2737921C/en active Active
- 2009-09-22 WO PCT/US2009/057931 patent/WO2010034032A2/en active Application Filing
- 2009-09-22 EP EP09736334.5A patent/EP2342221B1/en active Active
- 2009-09-22 CN CN2009801425171A patent/CN102203126A/zh active Pending
- 2009-09-22 EP EP18195669.9A patent/EP3492492A1/en not_active Withdrawn
- 2009-09-22 US US12/564,909 patent/US9206223B2/en active Active
- 2009-09-22 JP JP2011528083A patent/JP2012503025A/ja not_active Withdrawn
- 2009-09-22 BR BRPI0918838A patent/BRPI0918838A2/pt not_active Application Discontinuation
- 2009-09-22 CN CN201510159021.2A patent/CN104961795A/zh active Pending
- 2009-09-22 AU AU2009294875A patent/AU2009294875C1/en active Active
2011
- 2011-03-21 IL IL211837A patent/IL211837A/en active IP Right Grant
2012
- 2012-01-13 US US13/350,644 patent/US9394336B2/en not_active Expired - Fee Related
2015
- 2015-02-27 JP JP2015037711A patent/JP6196640B2/ja active Active
- 2015-10-23 US US14/921,573 patent/US20160115204A1/en not_active Abandoned
2017
- 2017-06-16 JP JP2017118507A patent/JP2017155063A/ja active Pending
- 2017-09-14 IL IL254498A patent/IL254498B/en active IP Right Grant
2019
- 2019-08-26 JP JP2019153604A patent/JP2019214614A/ja active Pending
- 2019-09-24 JP JP2019172908A patent/JP2020015748A/ja active Pending
2021
- 2021-07-23 US US17/383,675 patent/US20220017569A1/en not_active Abandoned
2023
- 2023-06-02 US US18/328,029 patent/US20240124518A1/en active Pending

Also Published As

Publication number	Publication date
EP2342221A2 (en)	2011-07-13
IL254498B (en)	2020-02-27
CN104961795A (zh)	2015-10-07
EP3492492A1 (en)	2019-06-05
JP2020015748A (ja)	2020-01-30
US20240124518A1 (en)	2024-04-18
JP2012503025A (ja)	2012-02-02
US9206223B2 (en)	2015-12-08
US9394336B2 (en)	2016-07-19
WO2010034032A3 (en)	2010-05-20
AU2009294875B2 (en)	2014-12-04
CA2737921C (en)	2019-01-15
US20120264674A1 (en)	2012-10-18
JP2015110654A (ja)	2015-06-18
EP2342221B1 (en)	2018-11-07
JP2019214614A (ja)	2019-12-19
IL254498A0 (en)	2017-11-30
IL211837A0 (en)	2011-06-30
AU2009294875A1 (en)	2010-03-25
JP6196640B2 (ja)	2017-09-13
JP2017155063A (ja)	2017-09-07
IL211837A (en)	2017-09-28
CA2737921A1 (en)	2010-03-25
CN102203126A (zh)	2011-09-28
AU2009294875C1 (en)	2015-05-14
US20220017569A1 (en)	2022-01-20
WO2010034032A2 (en)	2010-03-25
US20160115204A1 (en)	2016-04-28
US20100210515A1 (en)	2010-08-19

Publication	Publication Date	Title
BRPI0918838A2 (pt)	2015-12-08	processos para preparação de composições de polipeptídeos purificados
SMT201600307B (it)	2016-11-10	Composizione liposomiale
DE602008002756D1 (de)	2010-11-04	Bauzusammensetzung
BR112012001666A2 (pt)	2019-09-24	composições de proteína rsv f e métodos para fazer as mesmas
BRPI1013588A2 (pt)	2016-04-19	composição
BR112013008738A2 (pt)	2015-10-06	processos para purificação de proteínas
BRPI1013335A2 (pt)	2016-07-26	composição compósita
BRPI0906749A2 (pt)	2015-07-07	Composição
BRPI0913808A2 (pt)	2017-06-20	composição
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1015474A2 (pt)	2016-04-26	composição
FR2941462B1 (fr)	2013-07-05	Composition decapante
BRPI0918971A2 (pt)	2015-12-01	tienopirimidinas para composições farmacêuticas
BR112012012108A2 (pt)	2016-04-05	composição farmacêutica compreendendo propofol
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
EP2376105A4 (en)	2012-10-17	NKG2D-FC FOR IMMUNOTHERAPY
BRPI0917231A2 (pt)	2015-11-10	composição
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
BRPI1006632A2 (pt)	2016-08-16	composição catalisadora
EP2505644A4 (en)	2015-09-16	REGULATION COMPOSITION OF THE ATMOSPHERE
BRPI1011933A2 (pt)	2016-11-08	composição de purificação de gás ácido
BRPI1009749A2 (pt)	2016-03-15	composições de zircônia céria
BR112012010203A2 (pt)	2019-09-24	composição catalisadora apoiada
BRPI1005318A2 (pt)	2016-02-10	composição
BRPI1010198A2 (pt)	2016-03-29	composição de poliamida modificada

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-20	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2019-12-03	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements